Safety Alerts & Recalls
What does this mean?
Daptomycin (also known by the brand name Cubicin) is used to treat serious infections and so for most patients its benefits will continue to outweigh the risks. In general, the incidence of eosinophilic pneumonia linked to daptomycin use is thought to be very low, affecting around one patient in 10,000.
If you have been prescribed daptomycin you should continue to take it as normal, but if you develop symptoms of cough, fever and shortness of breath you should contact your doctor as soon as possible.
If you have any concerns about this alert or your treatment with daptomycin (Cubicin) please speak with your doctor or other healthcare professional.
Novartis Alerts Healthcare Professionals to The Association Of Eosinophilic Pneumonia With Daptomycin Use
Novartis has written to healthcare professionals to alert them to rare, but potentially serious reports, where daptomycin (Cubicin) use is linked to the development of eosinophilic pneumonia. Daptomycin is an antibiotic used to treat skin and soft tissue infections and endocarditis (inflammation of the inner lining of the heart).
Eosinophilic pneumonia is a condition where a type of white blood cell collects in the lungs, causing breathing difficulties. The most common symptoms of eosinophilic pneumonia are cough, fever and shortness of breath.The majority of cases of eosinophilic pneumonia linked to daptomycin use occurred after two weeks of treatment.
For more information please visit: more information here